Veeva Systems expanded its partnership with IQVIA, with IQVIA selecting additional Veeva clinical operations applications as enterprise standards for clinical development studies. The agreement covers CTMS, eTMF, Study Startup, and Site Connect tools, building on their previous EDC partnership. This expansion is expected to strengthen Veeva's presence in clinical research, improve trial efficiency, and create cross-selling opportunities, though financial terms and deployment timelines were not disclosed.

IQVIA Holdings (IQV), a clinical research and healthcare intelligence provider, is highlighted as a stock to watch with a Zacks Rank #3 (Hold) and VGM Score of B. The company has a Momentum Style Score of B with shares up 0.4% over the past four weeks. One analyst revised earnings estimates upward for fiscal 2026, with the Zacks Consensus Estimate at $12.92 per share and an average earnings surprise of +2.2%.

IQVIA reported Q2 2026 adjusted EPS of $3.15, up 12.1% YoY and beating consensus by 4.3%, with revenues of $4.37B up 8.7% and exceeding estimates. R&D Solutions new bookings surged 19% to $3.2B. However, the company faces liquidity concerns with a current ratio of 0.71 and net leverage at 3.6X adjusted EBITDA.

The global AI in clinical trials market is projected to expand from USD 2.09 billion in 2026 to USD 18.62 billion by 2040, growing at a 17.0% CAGR. AI applications including patient recruitment, predictive analytics, digital twins, and automation are addressing key challenges in drug development timelines and trial efficiency. Oncology represents the largest therapeutic area, while Asia-Pacific shows significant growth potential. Key players include IQVIA, Medidata, Dassault Systemes, and emerging AI companies like Deep 6 AI and AiCure.

Europe's clinical data analytics market is projected to reach USD 105.6 billion by 2031, growing at a 27% CAGR through 2033. Growth is driven by healthcare digitalization, AI adoption, cloud deployment, and regulatory initiatives like the European Health Data Space. Software and cloud-based solutions lead the market, with healthcare providers and payers increasingly investing in analytics for improved patient outcomes and operational efficiency.

The global rare disease CRO market is projected to grow from $2.07 billion in 2025 to $3.16 billion by 2030, with an 8.9% CAGR. Growth is driven by expanding gene and cell therapy pipelines, increasing orphan drug approvals, precision medicine adoption, and decentralized clinical trials. Key trends include AI integration, patient registries, and real-world evidence utilization.

IQVIA (IQV) has surged 60.1% over six months, driven by 6% organic growth in Q2 2026, with R&DS bookings up 19.3% and a $34.2 billion backlog. The company's rapid AI adoption—294 agents deployed across 90 use cases with 19 of top 20 pharma companies adopting solutions—is strengthening its competitive position and supporting sustained growth.

Veeva Systems raised its fiscal 2027 revenue guidance to $3.682-$3.687B (implying ~15% growth), driven by strong Vault CRM adoption with commitments from 12 of top 20 biopharma firms and 180+ live customers. The company's Falcon AI product has five early adopters, though execution remains a key near-term priority. While profitability is maintained with a 44% operating margin, newer initiatives like CRM migrations and AI monetization still require sustained execution.

TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.

Medera Inc. announced 12-month data from its MUSIC-HFpEF Phase 1/2a clinical trial showing that 80% of patients met the prespecified threshold for normalization of cardiac filling pressures, with approximately 30% reduction in peak exercise pulmonary capillary wedge pressure. The trial demonstrated a favorable safety profile with no treatment-related serious adverse events across all 10 treated patients. Results support advancement to a randomized Phase 2b trial for SRD-002, a single-dose intracoronary AAV1/SERCA2a gene therapy for heart failure with preserved ejection fraction.

The global eClinical Solutions market is projected to grow from USD 11.50 billion in 2025 to USD 42.55 billion by 2035, at a CAGR of 13.98%. Growth is driven by increased demand for efficient clinical trials, rising chronic disease prevalence, adoption of AI and cloud computing technologies, and decentralized trial models. Key players include Oracle, Veeva Systems, IQVIA, Medidata Solutions, and IBM Watson Health.

IQVIA CEO Ari Bousbib sold approximately 106,000 shares worth $26.1 million through an exercise-and-sell of expiring stock appreciation rights. The sale follows a strong Q2 earnings report with record clinical bookings of $3.15 billion and 8.7% revenue growth. Bousbib maintains a substantial 1.4 million share position, indicating the sale was routine calendar management rather than a bearish signal.